RALA and acute myeloid leukemia: AKT is just one of a number of client proteins (known or unknown) for HSP90 that may be targeted by ganetespib treatment and knockdown of multiple HSP90 clients such as KIT, Ral, JAK2 and members of the CDK family [5] may contribute to the observed high efficacy of this drug in primary AML samples.